➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Johnson and Johnson
Dow
Express Scripts
AstraZeneca

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for DDP-225


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for DDP-225?

DDP-225 is an investigational drug.

There have been 30 clinical trials for DDP-225. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2011.

The most common disease conditions in clinical trials are Carcinoma, Nasopharyngeal Neoplasms, and Esophageal Neoplasms. The leading clinical trial sponsors are Sun Yat-sen University, Peking University, and First Affiliated Hospital of Guangxi Medical University.

There are twelve US patents protecting this investigational drug and one hundred and forty-four international patents.

Recent Clinical Trials for DDP-225
TitleSponsorPhase
Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma(ESCC).Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 2
Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma(ESCC).Henan Cancer HospitalPhase 2
Efficacy and Safety of Albumin Paclitaxel Combined With Cisplatin Chemoradiotherapy for Non-resectable Stage III NSCLCGuizhou Medical UniversityN/A

See all DDP-225 clinical trials

Clinical Trial Summary for DDP-225

Top disease conditions for DDP-225
Top clinical trial sponsors for DDP-225

See all DDP-225 clinical trials

US Patents for DDP-225

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
DDP-225   Start Trial Use of 4-(2-Flurophenyl)-6-methyl-2-(1-piperazinyl)thieno(2,3-D)-pyrimidin- e for treating of urinary incontinence Arachnova Therapeutics Ltd. (Jersey, GB)   Start Trial
DDP-225   Start Trial 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D)pyrimidine in the treatment of functional bowel disorder Dynogen Pharmaceuticals, Inc. (Waltham, MA)   Start Trial
DDP-225   Start Trial Substituted phenoxy thiazolidinediones as estrogen related receptor-.alpha. modulators Janssen Pharmaceutica, NV (Beerse, BE)   Start Trial
DDP-225   Start Trial Substituted phenoxy N-alkylated thiazolidinediones as estrogen related receptor-.alpha. modulators Janssen Pharmaceutica N.V. (Beerse, BE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Medtronic
Harvard Business School
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.